Article

Evaluating ibrutinib, pirtobrutinib, remibrutinib, rilzabrutinib, and zanubrutinib in 34 BTK-variants at 7 inhibitor resistance sites

2026-04-23

Abstract excerpt

<title>Abstract</title> <p>Bruton tyrosine kinase (BTK) plays a central role in B-cell receptor signaling, and its inhibition has transformed the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL). Despite the success of BTK inhibitors (BTKi), resistance from acquired BTK mutations poses a significant clinical challenge. Here, we systematically characterized 34 BTK variants associated...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a7d3625c-91b5-55bd-b661-bd715a005bd9
DOI: 10.21203/rs.3.rs-9390771/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Evaluating ibrutinib, pirtobrutinib, remibrutinib, rilzabrutinib, and zanubrutinib in 34 BTK-variants at 7 inhibitor resistance sitesDOI 10.21203/rs.3.rs-9390771/v1Read

Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemiaSemantic proximity Read

BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.Semantic proximity Read

Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variantSemantic proximity Read

Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitorsSemantic proximity Read

Resistance to Bruton Tyrosine Kinase Inhibitors.Semantic proximity Read

BTK inhibitors in CLL: second-generation drugs and beyond.Semantic proximity Read

Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted TherapySemantic proximity Read

BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.Semantic proximity Read

Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.Semantic proximity Read

Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.Semantic proximity Read

A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.Semantic proximity Read